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Background: Alpha1-antitrypsin (AAT) deficiency is an under-diagnosed condition in patients
with chronic obstructive pulmonary disease (COPD). The objective of the present screening
was to estimate the AAT gene frequency and prevalence and to identify AAT deficiency cases
in a large cohort of Lithuanian patients with COPD.
Methods: A nationwide program of AAT deficiency was conducted in 1167 COPD patients,
defined according to the GOLD criteria. Patients were collected from outpatient clinics in five
different Lithuanian regions (Kaunas, Vilnius, Siauliai, Klaipeda and Alytus). AAT serum concen-
trations were measured by nephelometry; PI-phenotypes characterized by isoelectric-
focusing.
Results: Mean age and FEV1 were 62.0 (10.3) and 54.7% (10.9), respectively. Ninety-one AAT
deficiency genotypes (40 MZ, 39 MS, 1 SS, 3 SZ and 8 ZZ) were identified. Calculated PI*S
and PI)Z frequencies, expressed in per 1000, were 18.8 (95% CI: 13.9e25) and 25.3 (95% CI:
19.4e32.7), respectively. The calculated AAT gene prevalence (HardyeWeinberg principle)
was: 1/1.09 for MM, 1/28 for MS, 1/2814 for SS, 1/20 for MZ, 1/1049 for SZ and 1/1565 for
ZZ. Calculated Odds ratio (OR) for PI)Z in COPD vs. Lithuanian healthy people was of 1.87
(PZ 0.004).
Conclusion: The OR for each genotypic class demonstrated a significant increase of MZ, SZ and
ZZ genotypes in COPD patients. The results of the present study, with a significant number of37 326869; fax: þ370 37 326953.
skas@kmuk.lt (R. Sakalauskas).
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AAT deficiency screening in COPD in Lithuania 1655ZZ individuals detected, support the general concept of targeted screening for AAT deficiency
in countries like Lithuania, with a large population of COPD patients and low awareness among
care-givers about this genetic condition.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a prevalent
and costly disease characterized by progressive airflow
limitation. It arises as an abnormal inflammatory response
of the lung to long-term tobacco smoking or toxic gas
inhalation. The lung inflammation is further exacerbated by
oxidative stress and proteolytic damage by proteinases.1
The prevalence of COPD is appreciably higher in men over
40 years of age who are current or former heavy smokers.
However, there is a consistent evidence that only 15e30%
of smokers develop COPD, and that some non-smokers
may also develop chronic airflow obstruction, suggesting
that the risk for COPD results from a gene-environment
interaction.
The best described genetic risk factor for COPD is severe
hereditary deficiency of alpha1-antitrypsin (AAT),2 a genetic
disorder most commonly seen in Caucasians.3
AAT is a circulating serine proteinase inhibitor secreted
by the liver, which permeates most body tissues where it
acts as an inhibitor of a range of proteolytic enzymes.
About 100 genetic variants of AAT have been identified, but
most of the pathologies are related to AAT deficiency linked
to the Z allele: in clinical practice, 96% of AAT deficiency
patients have a ZZ genotype. The remaining 4% belong
mostly to SZ, and other rare deficiency (i.e., Mmalton and
Siiyama) or null genotypes.2
AAT deficiency is an under-diagnosed condition world-
wide. Recent guidelines from both the World Health
Organization and the American Thoracic Society/European
Respiratory Society recommend the establishment of
screening programs for the detection of AAT deficiency in
patients with COPD, since the detection of coincident AAT
deficiency could lead to family screening, appropriate
management (including lifestyle changes such as quitting
smoking and replacement therapy in selected cases), and
specific counselling for these patients and families.2,4
Therefore, the main objective of this study was to identify
the S and Z gene frequency in a cohort of 1167 COPD
patients from five main cities of Lithuania.
Methods
Sample sources and subjects selection
The study design was approved by the Regional Ethics
Committee of the Kaunas University of Medicine. During the
24 months from January 2005 to January 2007, 1580
patients with COPD were offered to participate in the
study through referral by 22 physicians from the different
Lithuanian regions (namely Kaunas, Vilnius, Siauliai, Klai-
peda and Alytus). A total of 1167 COPD patients, who gave
their informed consent, underwent further examination.Approximately 70% of the patients studied were previ-
ously diagnosed in outpatient medical clinics by primary
care-givers and referred to the referral hospital to confirm
diagnosis and start or review a proper management
regimen. The remaining 30% patients were identified in
hospital outpatient medical clinics by pulmonologists
during routine ambulatory follow-up visits or when they
were clinically stabilised after hospital discharge.
Only patients who met the GOLD1 spirometric criteria for
COPD: (1) ratio of post-bronchodilator forced expiratory
volume in 1 s (FEV1) to forced vital capacity (FVC) less
than 0.7, and (2) FEV1 less than 80% of the predicted value
were included in the study. After an appropriate physical
examination, data on the symptoms of the patient and
the diagnosis of COPD were also collected. Smoking history
was calculated in pack-years as the product of tobacco use
(in years) and the average number of cigarettes smoked per
day/20 (years cig. per day/20).
Sample collection and evaluation
Blood samples were drawn in serum tubes, clotted at room
temperature for 30e60 min and centrifuged for 15 min at
4000 rpm. Then, serum samples were immediately frozen
at 70 C for further assay. The serum concentrations of
AAT were determined by means of nephelometry using
commercially available kits (Dade Behring Marburg GmbH,
Germany) according to the manufacturer’s instructions.
The presence of PI)Z allele was checked by enzyme-linked
immunosorbent assay (ELISA) kits (Euro-Diagnostica/Wie-
slab, Sweden),5 qualitative method according to prepared
standard guidelines for the product. AAT phenotyping was
carried out by means of isoelectric-focusing (LKB Multiphor
II and LKB Macrodrive 5 Constant Power Supply, Amersham
Pharmacia Biotech, Piscataway, NJ, USA), as previously
described.6
Calculations and statistical analyses
The methodology used in the present study for AAT gene
frequency and prevalence calculations was the same as in
previous publications.3,4 Statistical comparisons were also
done with data from two previous studies on AAT genetic
epidemiology carried out on a total of 2491 Lithuanian
healthy adults.7,8 Data for the Lithuanian population were
obtained from Statistics Lithuania.9 Descriptive statistics
were used to tabulate the primary cohort database. Quan-
titative variables were expressed as means with standard
deviations (SD). The values of serum AAT concentration
were compared using Student’s t-test. Some data were
analyzed using the KruskaleWallis test and the ManneWhit-
ney U-test. The Statistical Package for the Social Sciences
software program was used to perform statistics analysis
[SPSS Ibe´rica, Madrid, Spain]. The value of P< 0.05 was
accepted for statistical significance.
Table 1 Demographic characteristics, AAT genotypes, spirometric values and AAT serum concentrations from a Lithuanian
cohort of 1167 COPD patients
AAT
genotypes
N Sex
% M
Age (SD) Cumulative
pack-years (SD)
FEV1/FVC
(SD)
FEV1% pred. AAT serum
concentration
MM 1076 84 66 (10.4) 22.4 (12.4) 54.8 (10.5) 46 (15.8) 164.7 (39.8)
MS 39 56 64 (7.8) 20.4 (11.6) 55.7 (11.2) 50.8 (16.1) 102 (11)
MZ 40 65 67 (11.2) 21.3 (12) 58.6 (9.5) 51.5 (14.5) 99 (14)
SS 1 0 61 22 () 65 48 88
SZ 3 66 63 (2.8) 18 (2.8) 56.5 (6.3) 70 (4.2) 77(19.7)
ZZ 8 62 54 (11.3) 19 (11) 36.2 (18.6) 38.5 (18.1) 30 (12.4)
Total 1167 82 62 (10.3) 22.1 (12.2) 54.7 (10.9) 46.5 (15.9) 158 (43.6)
P-value Between all genotypic classes 0.065 0.877 0.001 0.69 0.000
ZZ vs. remaining groups 0.06 0.538 0.010 0.306 0.000
Data are presented as mean or %, unless otherwise stated. N: number; P: statistical significance level (<0.05); AAT: alpha1-antitrypsin;
%: percent; SD: standard deviation; M: males; FEV1: forced expiratory volume in one second expressed in percent of the predicted
normal value. AAT serum concentrations measured by nephelometry, values expressed in mg/dL.
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As shown in Table 1, the cohort consisted of 1167 patients
(82% males and 18% females) with moderate to severe
COPD. The distribution of genotypes (number and
percentage) was: 1076 (92.2%) MM, 40 (3.4%) MZ, 39
(3.3%) MS, 1 (0.1%) SS, 3 (0.3%) SZ and 8 (0.7%) ZZ. The
mean age of the cohort was 62 years (10.3). The ZZ group
compared to all the remaining groups was younger (54
years) but not significantly (PZ 0.06). Nearly 83% of the
patients was current (57.6%) or former (25.2%) smokers of
22.1 12.2 pack-years and 17.2% never smoked. Smoking
status (pack-years) did not significantly differ between
the current and former smoker groups. The mean value of
FEV1 was 46.5 (15.9), and the mean value of the ratio
FEV1/FVC was 54.7 (10.9). There was no significant differ-
ence among all groups in FEV1. The ZZ group showed a lower
FEV1/FVC (36.0, PZ 0.010) compared to other genotype
groups. The mean AAT serum concentration (mg/dL) was
of 158 (43.6). As expected, we found significant differences
in AAT serum concentrations between groups (PZ 0.000),
although there was an overlap among MS, MZ and SS AAT
concentrations. The ZZ group showed a significantly lower
AAT serum concentration (30 mg/dL, PZ 0.000) relative
to the other genotype groups.
Calculated gene frequencies for PI)S and PI)Z were 18.8
(13.9e25) and 25.3 (19.4e32.7) per 1000 (Table 2). Calcu-
lated prevalence of different AAT genotypes was: 1/1.09Table 2 Estimated PI*S and PI*Z gene frequency and genotype p
joined cohorts of 2491 healthy unrelated people (Refs. 7,8) from
Samples Gene frequency per 1000 (95% CI) Hardye
PI*S PI*Z MS
COPD N: 1167 18.8 (13.9e25.4) 25.3 (19.4e32.7) 28
Healthy unrelated
people N: 2491
15.6 (12.5e19.6) 13.6 (10.7e17.4) 33
95% CI: 95% confidence intervals. Calculated Odds Ratio for Z and S a
2.70), PZ 0.0004 and 1.21(0.82e1.78), PZ 0.320.for MM, 1/28 for MS, 1/2814 for SS, 1/20 for MZ, 1/1049
for SZ and 1/1565 for ZZ. Two previous studies of AAT
genetic epidemiology in Lithuanian healthy adults showed
a mean gene frequency (expressed in per 1000) of 15.6
(95% IC: 12e20) for S and 13.6 (95% IC: 11e19) for Z.7,8
The odds ratio (OR) for PI)Z between COPD and healthy
Lithuanian adults was 1.87 (1.30e2.70), PZ 0.0004.Discussion
In the current study, we show for the first time that the
PI)Z gene frequency is about two-fold higher among COPD
patients compared to the general population of Lithua-
nia.7,8 The odds ratios for each genetic group among
COPD patients were lower in the normal MM genotype, as
predicted in the MS and SS deficiency genotypes, but signif-
icantly higher in the MZ, SZ, and ZZ deficiency genotypes.
The most striking finding of the COPD cohort screening
was the high number of ZZ genotypes. The ZZ patients
showed very low serum concentrations of AAT, poorer spiro-
metric values, and they were younger than the remaining
COPD patients. Most of the studied COPD patients were
men (82%). The prevalence of men among COPD patients
in Lithuania could be explained by smoking habits. Accord-
ing to the Finbalt Health Monitor program, the number of
men smokers in the general Lithuanian population is 6.9
times higher than the number of women smokers.10revalence (MS, SS, MZ, SZ and ZZ) in 1167 COPD patients and
Lithuania
Weinberg equilibrium calculated prevalence (1/x)
SS MZ SZ ZZ Total
2814 20 1049 1565 11.6
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Figure 1 Distribution of PI)S and PI)Z gene frequencies (expressed in 1000) in Northern Europe countries.
AAT deficiency screening in COPD in Lithuania 1657Overall, the results of our study show both similarities
and differences to those reported in other European
countries, where AAT deficiency detection programs have
been carried out using different methodologies. For
example, case control studies in other countries also
showed an increase in the prevalence of PI)Z heterozy-
gotes among patients with COPD compared with the control
group (OR for the MZ phenotype: between 1.5 and 5).11e14
The case-detection program of 2137 COPD patients in Spain
revealed seven cases of ZZ deficiency (0.37%).11 In another
study undertaken in Italy, the detection rate for ZZ was
6.4%.12 The higher rate of ZZ cases in the latter could be
due to the design of the study, since only COPD patients
with familial or clinically inferred AAT deficiency were
selected. In contrast, another program carried out in Ger-
many13 with 1060 patients showed no subjects with the
ZZ phenotype. This is probably related to the sample
composition which included individuals with different types
of chronic respiratory diseases. In contrast, a recent study
performed in Germany using a targeted screening program
with 2272 subjects identified 335 patients with severe ZZ
AAT deficiency, including 16 individuals with rare geno-
types.14 Our results closely parallel to the data received
from a study carried out in Denmark where the frequency
of AAT deficiency among COPD patients was found to be
0.8% for ZZ and 2.4% for MZ genotype.15
The highest incidence of the PI)S allele in Northern
Europe (around 20e30 per 1000) is found in the South of
the Scandinavian Peninsula, followed by Latvia, and Den-
mark, and it significantly decreases through the North and
the East. The Z deficiency allele is exceptionally high in
Latvia relative to other countries worldwide, followed bysouthern Norway, Denmark, Southern Sweden and Estonia,
and in decreasing frequency in Lithuania, Finland, Europe
Russia and Iceland.16 Previous studies performed by other
investigators in the general population of Lithuania7,8
reported a moderate prevalence of both S and Z alleles
compared to other Northern Europe countries (Fig. 1).
The prevalence of COPD in Lithuania has not been
reported, but it is estimated to be similar to that in other
European countries: 8e10% in the population >40 years.17
This implies that w150,000 Lithuanian people may suffer
from this disease, and that approximately 100 ZZ subjects
remain undiagnosed in the COPD population. The results
of the present study support the general concept of tar-
geted screening for AAT deficiency in other Northern
European countries with a high frequency of PI)Z and
a large population of COPD patients.
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